RATIONALE-209 Trial Design and Patient Population

This study was an open-label, single-arm Phase 2 clinical trial conducted on 80 patients with progressive or metastatic MSI-H (microsatellite instability-high) and dMMR (mismatch repair deficient) solid tumors who had prior treatment experience. MSI-H/dMMR is a biomarker that appears in various organs and is not limited to specific cancer types, and it is a representative characteristic of the tumor microenvironment in which immune checkpoint inhibitors show very high response rates. The single-arm design without a control group can be interpreted as a strategic choice to rapidly demonstrate the efficacy of biomarker-based targeted therapy and obtain conditional approval from regulatory agencies. It is clinically significant in that it provides a new treatment option for patients who have failed conventional chemotherapy and have no alternative treatments.

Mechanism of Tevimbra and RATIONALE-209 Trial Results

BeiGene's Tevimbra (tislelizumab) is a monoclonal antibody that targets the PD-1 protein and blocks the immune inhibitory signals of T cells. In this trial, Tevimbra achieved an objective response rate (ORR) of 46.7%, demonstrating a statistically significant improvement in efficacy compared to the historical control group's response rate of 10% (P-value < 0.0001). In particular, the median progression-free survival (mPFS) and median overall survival (mOS) were not reached in the long-term follow-up of 28.9 months, demonstrating the durability of the drug's efficacy. This shows that Tevimbra can strongly inhibit the immune evasion mechanism of cancer cells and extend the patient's survival benefit.

Regulatory Approval History and Global Market Presence

Based on clinical data, Tevimbra received formal marketing approval from the China National Medical Products Administration (NMPA) for the indication of MSI-H/dMMR solid tumors on March 11, 2022. However, the U.S. Food and Drug Administration (FDA) has currently approved it only for specific indications such as esophageal squamous cell carcinoma (ESCC) and gastric cancer, and there is a regulatory gap in that it has not yet received formal approval for MSI-H/dMMR cancers. To bridge the global regulatory gap, BeiGene is expected to continue to explore the expansion of indications to North America and Europe, building on its successful launch in the Asian market. Obtaining regulatory approval will be a key catalyst for driving Tevimbra's revenue growth in future global commercialization.

Building an Independent Strategy and Competitive Landscape in the Immuno-Oncology Market

In September 2023, BeiGene and Novartis mutually agreed to terminate their global co-development and licensing agreement for Tevimbra, and BeiGene regained exclusive rights worldwide. The original agreement included a total of $2.2 billion, including a $650 million upfront payment and $1.55 billion in milestone payments, but now BeiGene can exclusively commercialize the drug worldwide without paying royalties. The MSI-H/dMMR market is currently dominated by Merck's Keytruda and GSK's Jemperli, and Tevimbra faces the challenge of securing market share through price competitiveness and diversification of indications. In the MSI-H/dMMR therapeutic market, which is expected to grow rapidly to approximately $21.13 billion by 2030, fierce competition for market share is expected with global large pharmaceutical companies that have exclusive rights.